Patents Assigned to FRED
  • Immunomodulatory fusion proteins and uses thereof
    Patent number: 11725210
    Abstract: The present disclosure relates to immunomodulatory fusion proteins containing an extracellular binding domain and an intracellular signaling domain, wherein binding of a target can generate a modulatory signal in a host cell, such as a T cell. The present disclosure also relates to uses of immune cells expressing such immunomodulatory fusion proteins to treat certain diseases, such as cancer or infectious disease.
    Type: Grant
    Filed: March 16, 2018
    Date of Patent: August 15, 2023
    Assignee: Fred Hutchinson Cancer Center
    Inventors: Shannon K. Oda, Philip D. Greenberg, Thomas M. Schmitt
  • SYSTEMS AND METHODS TO PRODUCE B CELLS GENETICALLY MODIFIED TO EXPRESS SELECTED ANTIBODIES
    Publication number: 20230250159
    Abstract: Systems and methods to genetically modify B cells to express selected antibodies are described. The systems and methods can be used to: obviate the need for classical vaccinations; provide protection against infectious agents for which no vaccinations are currently available; provide protection against infectious agents when patients are otherwise immune-suppressed; and/or provide a benefit provided by a therapeutic antibody, such as in the treatment of autoimmune disorders.
    Type: Application
    Filed: February 8, 2023
    Publication date: August 10, 2023
    Applicant: Fred Hutchinson Cancer Center
    Inventors: Justin J. Taylor, Howell F. Moffett
  • Compositions and methods for detecting allogeneic matter in a subject
    Patent number: 11718876
    Abstract: The present disclosure provides a panel of nucleic acid molecule primers specific for HLA-specific alleles and other genetic polymorphisms, which are useful for quantitatively amplifying these markers to detect, diagnose, and monitor individuals who have or are at risk of certain disease conditions, such as autoimmune disease, proliferative disease, infectious disease, allograft rejection, or pregnancy-related pathologies.
    Type: Grant
    Filed: June 17, 2021
    Date of Patent: August 8, 2023
    Assignee: Fred Hutchinson Cancer Center
    Inventors: J. Lee Nelson, Nathalie C. Lambert, Vijayakrishna K. Gadi, Zhen Yan
  • Compositions and methods for detecting allogeneic matter in a subject
    Patent number: 11718875
    Abstract: The present disclosure provides a panel of nucleic acid molecule primers specific for HLA-specific alleles and other genetic polymorphisms, which are useful for quantitatively amplifying these markers to detect, diagnose, and monitor individuals who have or are at risk of certain disease conditions, such as autoimmune disease, proliferative disease, infectious disease, allograft rejection, or pregnancy-related pathologies.
    Type: Grant
    Filed: February 19, 2020
    Date of Patent: August 8, 2023
    Assignee: Fred Hutchinson Cancer Center
    Inventors: J. Lee Nelson, Nathalie C. Lambert, Vijayakrishna K. Gadi, Zhen Yan
  • System for managing incontinence
    Patent number: 11717450
    Abstract: The invention relates to an incontinence monitoring system including a plurality of electrodes on an absorbent article including an absorbent core and a device for electrical connection with the electrodes and monitoring one or more electrical properties of the electrodes. A first set of the electrodes are adapted for detection of wetness associated with urinary incontinence events, and a second set of the electrodes are adapted for detection of faecal incontinence events. The invention also relates to an absorbent article, sensor and device as well as methods for monitoring incontinence.
    Type: Grant
    Filed: November 7, 2018
    Date of Patent: August 8, 2023
    Assignee: Fred Bergman Healthcare Pty Ltd
    Inventors: Peter Curran, Kenneth Huynh
  • AUGMENTING ANTIGEN-NEGATIVE CELL DEATH IN ANTIGEN-TARGETED IMMUNOTHERAPIES
    Publication number: 20230218669
    Abstract: Combination therapies that include (i) an immune cell that expresses a chimeric antigen receptor (CAR) or similar molecule and (ii) a compound that preserves or potentiates the in vivo actions of tumor necrosis factor alpha (TNF?) against cancer cells are described. The combination therapies result in the killing of antigen-negative cells in the vicinity of immunotherapy targeted-antigen-positive cells reducing the survivability of escape variants and providing other benefits.
    Type: Application
    Filed: March 31, 2021
    Publication date: July 13, 2023
    Applicant: Fred Hutchinson Cancer Center
    Inventors: Cameron J. Turtle, Salvatore Fiorenza
  • CHIMERIC ANTIGEN RECEPTORS TARGETING CD33
    Publication number: 20230220103
    Abstract: Chimeric antigen receptors (CARs) with binding domains derived from a novel suite of human CD33-binding antibodies are described. The CARs include optimized short and intermediate spacer regions. The current disclosure also provides methods of cell expansion/activation processes utilizing IL-2, IL-7, IL-15, and/or IL-21 that improve cellular proliferation and cell lysis of the CARs as described.
    Type: Application
    Filed: March 31, 2021
    Publication date: July 13, 2023
    Applicant: Fred Hutchinson Cancer Center
    Inventors: Cameron J. Turtle, Roland B. Walter, George S. Laszlo, Salvatore Fiorenza
  • NEUTRALIZING MONOCLONAL ANTIBODIES AGAINST COVID19
    Publication number: 20230212266
    Abstract: The disclosure provides antibodies, antibody fragments, and antibody derivatives that bind to the viral envelope spike protein (S2P) of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), and related compositions, and methods. In some embodiments, the antibodies, antibody fragments, and antibody derivatives bind to an epitope of the receptor binding domain (RBD) of SARS-CoV-2.
    Type: Application
    Filed: April 26, 2021
    Publication date: July 6, 2023
    Applicant: Fred Hutchinson Cancer Center
    Inventors: Leonidas Stamatatos, Andrew McGuire, Marie Pancera
  • BIOMARKERS FOR DETECTION OF LUNG CANCER
    Publication number: 20230213521
    Abstract: The application discloses in vitro methods for diagnosing lung cancer in a subject, wherein the method comprises detecting at least one biomarker selected from the group consisting of Rho GDP dissociation inhibitor beta (ARHGDIB), alpha-tubulin 4A (TUBA4A), glutathione S-transferase omega 1 (GSTO1), filamin A (FLNA), peroxiredoxin 6 (PRDX6) and cadherin 13 (CDH13) in a biological sample from the subject, and kits for measuring said at least one biomarker.
    Type: Application
    Filed: April 28, 2021
    Publication date: July 6, 2023
    Applicants: Luxembourg Institute of Health (LIH), Fred Hutchinson Cancer Center, The Translational Genomics Research Institute (TGEN)
    Inventors: Victoria EL KHOURY, Anna Elisabeth SCHRITZ, Yeoun Jin KIM, Guy BERCHEM, Amanda PAULOVICH, Jeffrey WHITEAKER, Konstantinos PETRITIS, Patrick PIRROTTE, Tony TEGELER
  • MYELOMA-SPECIFIC IMMUNITY REQUIRES THE DIFFERENTIATION OF STEM-LIKE MEMORY T CELLS IN THE BONE MARROW
    Publication number: 20230201262
    Abstract: Methods for treating malignancies such as hematological malignancies, including myeloma, that are resistant to tissue transplant treatments and that can be characterized by an increased risk of relapse or graft-versus-host disease (GVHD). A method for treatment includes transplanting a tissue that includes T cells to a subject, enriching for a stem-like memory T cell phenotype in the T cells, and stimulating the T cells to enhance a graft-versus-tumor (GVT) response of the T cells. The enriching for the stem-like memory T cell phenotype can include depletion of exhausted alloreactive T cells with a post-transplant cyclophosphamide (PT-Cy) treatment and the stimulating the T cells can include an agonist immunotherapy, such as a decoy-resistant IL-18 (DR-18) treatment, to enhance the GVT response.
    Type: Application
    Filed: December 6, 2022
    Publication date: June 29, 2023
    Applicant: Fred Hutchinson Cancer Center
    Inventors: Simone Minnie, Geoffrey Hill
  • ANTI-CD33 ANTIBODIES AND USES THEREOF
    Publication number: 20230190810
    Abstract: A suite of novel anti-CD33 antibodies is described. The provided antibodies are pan-binders, binding the C2-set Ig-like domain in the presence or absence of the V-set Ig-like domain of CD33; are C2-set specific binders, binding the C2-set Ig-like domain only in the absence of the V-set Ig-like domain of CD33; or are V-set binders, binding the V-set Ig-like domain of CD33. The antibodies provide novel therapeutic and diagnostic tools against CD33-related disorders, such as acute myeloid leukemia (AML).
    Type: Application
    Filed: March 31, 2021
    Publication date: June 22, 2023
    Applicant: Fred Hutchinson Cancer Center
    Inventors: Roland B. Walter, George S. Laszlo
  • COMPOSITIONS AND METHODS FOR ENHANCING CANCER IMMUNOTHERAPY
    Publication number: 20230190707
    Abstract: The disclosure provides methods of enhancing susceptibility of neoplastic, transformed, and/or cancer cells (“cancer cells”) to immunotherapeutic agents. The methods comprise contacting the cancer cell with an agent that modulates RNA splicing. In some embodiments, the method further comprise contacting the cancer cell with the immunotherapeutic agent, such as an immune checkpoint inhibitor. The disclosure also provides compositions and/or methods for treating a subject with cancer. In some embodiments, the disclosure provides compositions and methods for combination therapy that comprises administering to a subject with cancer an effective amount of an agent that modulates RNA splicing and a therapeutically effective amount of an immunotherapeutic agent, such as an immune checkpoint inhibitor.
    Type: Application
    Filed: May 14, 2021
    Publication date: June 22, 2023
    Applicants: Fred Hutchinson Cancer Center, Memorial Sloan Kettering Cancer Center
    Inventors: Robert K. Bradley, Omar Abdel-Wahab, Sydney Lu
  • STRATEGIES TO ASSESS AND/OR PRODUCE CELL POPULATIONS WITH PREDICTIVE ENGRAFTMENT POTENTIAL
    Publication number: 20230159895
    Abstract: Strategies to assess and/or produce cell populations with predictive engraftment potential are described. The cell populations can be used for a variety of therapeutic and research purposes.
    Type: Application
    Filed: November 18, 2022
    Publication date: May 25, 2023
    Applicant: Fred Hutchinson Cancer Center
    Inventors: Stefan Radtke, Hans-Peter Kiem, Jennifer E. Adair
  • METHODS AND COMPOSITIONS COMPRISING BRD9 ACTIVATING THERAPIES FOR TREATING CANCERS AND RELATED DISORDERS
    Publication number: 20230159920
    Abstract: The current disclosure relates to methods and compositions for increasing functional expression of BRD9 in a cell. The methods and compositions can be incorporated into methods for treating cancer through the administration of BRD9 activating therapies. Accordingly, aspects of the disclosure relate to compositions and methods for treating cancer, a pre-malignant disease, or a dysplastic disease in a subject. The method can comprise administering a BRD9 activating therapy to the subject.
    Type: Application
    Filed: June 25, 2020
    Publication date: May 25, 2023
    Applicants: Fred Hutchinson Cancer Research Center, Memorial Sloan Kettering Cancer Center
    Inventors: Robert K. Bradley, Omar Abdel-Wahab, Daichi Inoue
  • METHODS AND COMPOSITIONS TO ENHANCE HUMORAL IMMUNITY TO REDUCE CYTOMEGALOVIRUS INFECTION AND REACTIVATION BY IL-6 INHIBITION
    Publication number: 20230151101
    Abstract: Embodiments of the present disclosure are directed to methods and compositions for inhibiting cytomegalovirus (CMV) in a transplant recipient. In some embodiments, the methods are directed to inhibiting CMV reactivation in a transplant recipient with a CMV-seropositive serological status, the method comprising administering an effective amount of a compound to block IL-6 function. In some embodiments, the methods are directed to preventing CMV infection in a transplant recipient, wherein a transplant donor has a CMV-seropositive serological status, the method comprising administering an effective amount of a compound to block IL-6 function. In still other embodiments, a composition comprising a compound to block IL-6 function is administered to a transplant recipient with a CMV-seropositive serological status to prevent CMV reactivation.
    Type: Application
    Filed: January 11, 2022
    Publication date: May 18, 2023
    Applicant: Fred Hutchinson Cancer Research Center
    Inventors: Geoffrey Hill, Siok Tey, Mariapia Degli-Esposti
  • CHIMERIC ANTIGEN RECEPTORS TARGETING CD33
    Publication number: 20230151094
    Abstract: Chimeric antigen receptors (CARs) with binding domains derived from a novel suite of CD33-binding antibodies are described. The CARs include optimized short and intermediate spacer regions. The current disclosure also provides methods of cell expansion/activation processes utilizing IL-2, IL-7, IL-15, and/or IL-21 that improve cellular proliferation and cell lysis of the CARs as described.
    Type: Application
    Filed: March 31, 2021
    Publication date: May 18, 2023
    Applicant: Fred Hutchinson Cancer Center
    Inventors: Cameron J. Turtle, Roland B. Walter, George S. Laszlo, Salvatore Fiorenza
  • Cartilage-homing peptides
    Patent number: 11648290
    Abstract: Peptides that home, target, migrate to, are directed to, are retained by, or accumulate in and/or binds to the cartilage of a subject are disclosed. Pharmaceutical compositions and uses for peptides or peptide-active agent complexes comprising such peptides are also disclosed. Such compositions can be formulated for targeted delivery of a drug to a target region, tissue, structure or cell in the cartilage. Targeted compositions of the disclosure can deliver peptide or peptide-active agent complexes to target regions, tissues, structures or cells targeted by the peptide.
    Type: Grant
    Filed: June 21, 2021
    Date of Patent: May 16, 2023
    Assignees: FRED HUTCHINSON CANCER CENTER, BLAZE BIOSCIENCE, INC.
    Inventors: James Olson, Andrew David Strand, Emily June Girard, Roland Strong, Christopher Mehlin, Colin Correnti, Natalie Nairn
  • HUMAN ANTI-CD33 ANTIBODIES AND USES THEREOF
    Publication number: 20230144405
    Abstract: A suite of novel human anti-CD33 antibodies is described. The provided antibodies are pan-binders, binding the C2-set Ig-like domain in the presence or absence of the V-set Ig-like domain of CD33 or are V-set binders, binding the V-set Ig-like domain of CD33. The antibodies provide novel therapeutic and diagnostic tools against CD33-related disorders, such as acute myeloid leukemia (AML).
    Type: Application
    Filed: March 31, 2021
    Publication date: May 11, 2023
    Applicant: Fred Hutchinson Cancer Center
    Inventors: Roland B. Walter, George S. Laszlo
  • CONDITIONING REGIMENS FOR IN VIVO GENE THERAPY
    Publication number: 20230133243
    Abstract: The present disclosure provides, among other things, immune suppression regimens for in vivo gene therapy and uses thereof. In various embodiments of the present disclosure, in vivo gene therapy includes delivery of at least one exogenous coding nucleic acid sequence to a stem cell of the subject. Success of in vivo gene therapy can be inhibited or reduced by immunotoxicity. The present disclosure provides compositions and methods, including among other things immune suppression regimens, that reduce immunotoxicity of in vivo gene therapy, e.g., in vivo gene therapy including administration of a viral gene therapy vector to a subject.
    Type: Application
    Filed: April 12, 2021
    Publication date: May 4, 2023
    Applicants: Fred Hutchinson Cancer Center, University of Washington
    Inventors: Andre Lieber, Hans-Peter Kiem
  • ANTIBODY-BASED COMPOSITIONS FOR TARGETING TROPOMYOSIN RECEPTOR KINASE B (TRKB) ISOFORMS
    Publication number: 20230103618
    Abstract: In some aspects, the disclosure provides antibody-based reagents that specifically bind a tropomyosin receptor kinase B (TrkB) isoform that is associated with cancers. In some embodiments, the isoform is TrkB.T1. In some embodiments, the antibody or antibody derivative specifically binds a polypeptide comprising, consisting essentially of, or consisting of the sequence FVLFHKIPLDG (SEQ ID NO:1), or a sequence with at least 80% sequence identity thereto. In other aspects, the disclosure provides methods of producing the antibody or antibody derivative, related hybridomas, and methods of detecting and treating cancers incorporating use of the disclosed antibody reagents.
    Type: Application
    Filed: January 29, 2021
    Publication date: April 6, 2023
    Applicant: Fred Hutchinson Cancer Center
    Inventors: Eric Holland, Siobhan Pattwell